- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07856797
A Study to Confirm Safety and Effectiveness of RADIESSE® Injectable Implant for the Correction of Moderate to Severe Nasolabial Folds (Radiesse China)
A Prospective, Open-Label, Multicenter, Post-Market Clinical Follow-Up Study to Confirm the Long-term Safety and Effectiveness of RADIESSE® Injectable Implant for the Correction of Moderate to Severe Nasolabial Folds
The purpose of this study is to confirm the long-term safety, effectiveness, and degradation profile of RADIESSE® Injectable Implant for the correction of moderate to severe nasolabial folds (NLFs) in Chinese adults. Eligible participants will receive treatment with RADIESSE® Injectable Implant in both NLFs and may receive an optional touch-up treatment at Month 1 at investigator's discretion. Participants will be followed for up to 24 months after last treatment.
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Public Disclosure Manager
- Phone Number: +1 984-301-3095
- Email: Aesthetic.Trials@merz.com
Study Locations
-
-
-
Beijing, China, 100034
- Recruiting
- Merz Investigative Site
-
Changde, China, 415000
- Recruiting
- Merz Investigative Site
-
Chengdu, China, 610021
- Recruiting
- Merz Investigative Site
-
Gaozhou, China, 525200
- Recruiting
- Merz Investigative Site
-
Hangzhou, China, 311200
- Recruiting
- Merz Investigative Site
-
Nanjing, China, 210029
- Recruiting
- Merz Investigative Site
-
Xianyang, China, 712099
- Recruiting
- Merz Investigative Site
-
Yibin, China, 644000
- Recruiting
- Merz Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- WSRS score of 3 (moderate) or 4 (severe) in both right and left NLFs, as determined live by the treating investigator. The WSRS score for the right and the left NLF does not have to be equal.
- Willing to abstain from other aesthetic treatments in the NLF area during study participation.
Exclusion Criteria:
- Prior dermal filler or implant material detectable in the NLF area by ultrasound.
- Active infection or acute inflammation at treatment sites.
- Hyaluronic Acid or collagen filler treatment in NLFs within 12 months.
- CaHA or Poly L-Lactic Acid filler treatment in NLFs within 24 months.
- Recent facial dermal therapies in the midface region within the past 6 months.
- Prior facial surgery or implants that could interfere with assessments.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: RADIESSE® Injectable Implant
Participants will receive a single injection of RADIESSE® administered to both NLFs on Day 1. Participants may receive an optional touch-up injection at Month 1 following the initial treatment at investigator's discretion. RADIESSE® will be administered according to the current product labelling and instruction for use. |
Participants will receive treatment with RADIESSE® Injectable Implant.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants Achieving at Least a 1-point Improvement in Both NLFs From Baseline to Month 6 after Last Treatment on the Wrinkle Severity Rating Scale (WSRS), as Assessed Live by the Treating Investigator
Time Frame: At Month 6 after last treatment
|
Severity of the NLFs was assessed and measured using the 5-point WSRS, where 1=absent and 5=extreme. A lower score indicates better outcome. |
At Month 6 after last treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants Achieving Improvement (Score of 1, 2, 3) on the Investigator Global Aesthetic Improvement Scale (iGAIS) at Month 6 After Last Treatment, as Assessed Live by the Treating Investigator
Time Frame: At Month 6 after last treatment
|
The iGAIS is an assessment grading scale where the treating investigator describes the degree of improvement in facial appearance according to the GAIS, a 5-point scale ranging from 'Very Much Improved' (1) to 'Worse' (5). The investigator will be asked to rate the NLFs and select the rating that best applies when asked "What is the overall impression of aesthetic change of the participants NLFs due to treatment, compared to the pretreatment photograph". Improvement is defined as a rating of +1, +2, or +3. The higher the iGAIS score, the greater the improvement. |
At Month 6 after last treatment
|
|
Percentage of Participants Achieving Improvement (Score of 1, 2, 3) on the Participant Global Aesthetic Improvement Scale (pGAIS) at Month 6 After Last Treatment, as Assessed Live by Participant
Time Frame: At Month 6 after last treatment
|
The pGAIS is a self-assessment grading scale where the participant independently describes the degree of improvement in facial appearance according to the GAIS, a 5-point scale ranging from 'Very Much Improved' (1) to 'Worse' (5). Participants will be asked to rate the NLFs and select the rating that best applies when asked "What is the overall impression of aesthetic change of your NLFs due to treatment, compared to the pretreatment photograph?" Improvement is defined as a rating of +1, +2, or +3. The higher the pGAIS score, the greater the improvement. |
At Month 6 after last treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Merz Medical Expert, Merz North America, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- RAD-NLF-CN003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.